Resources

Publications

05/23/2024
- Oncology
Clinicopathologic and molecular landscape of invasive mucinous adenocarcinoma of the lung
ASCO 2024
05/23/2024
- Oncology
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
ASCO 2024
05/23/2024
- Oncology
Comparison of tumor immune microenvironments (TIMEs) between primary and metastatic sites (Mets) in triple-negative breast cancer (TNBC)
ASCO 2024
05/23/2024
- Oncology
TriHealth Cancer Institute’s collaboration with the Tempus AI TIME program impact on clinical trial operations and enrollment
ASCO 2024
05/23/2024
- Oncology
Comparing the somatic, germline, and immune landscapes of upper tract urothelial carcinoma (UTUC) and UC of the bladder (UCB)
ASCO 2024
05/22/2024
- Oncology
A Comprehensive Analysis of POLE/POLD1 Genomic Alterations in Colorectal Cancer
The Oncologist
05/10/2024
- Oncology
Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies
Cancers
05/09/2024
- Oncology
Evolving From Discrete Molecular Data Integrations to Actionable Molecular Insights Within the Electronic Health Record
JCO Clinical Cancer Informatics
05/09/2024
- Oncology
Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-Small Cell Lung Cancer
Clinical Lung Cancer
05/02/2024
- Oncology
Real-World Clinical Genomics Study of HR+/HER2- Metastatic Breast Cancers Treated by CDK4/6i Plus Endocrine Therapies Revealed a Drug Resistant Tumor Segment Characterized by ER Independence
SABCS 2023

19 20 21